Interferon-beta for treatment of rheumatoid arthritis?

Arthritis Res. 2002;4(6):346-52. doi: 10.1186/ar598. Epub 2002 Sep 18.


IFN-beta treatment is emerging as a potentially effective form of therapy in various immune-mediated conditions. The present review addresses the possible role of IFN-beta in immune-mediated diseases such as multiple sclerosis and rheumatoid arthritis. Several placebo-controlled trials are discussed, as are the available immunological data that are relevant to this field. Review of these data provides evidence that IFN-beta has some beneficial therapeutic effect in patients with relapsing-remitting multiple sclerosis and might also have antirheumatic potential. This notion is supported by recent studies showing a critical role for IFN-beta in bone homeostasis.

Publication types

  • Review

MeSH terms

  • Animals
  • Arthritis, Experimental / drug therapy
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / physiopathology
  • Clinical Trials, Phase I as Topic
  • Disease Models, Animal
  • Humans
  • Immunologic Factors / therapeutic use*
  • Interferon-beta / physiology
  • Interferon-beta / therapeutic use*
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy
  • Multiple Sclerosis, Relapsing-Remitting / physiopathology
  • Recombinant Proteins


  • Immunologic Factors
  • Recombinant Proteins
  • Interferon-beta